A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

PHASE3CompletedINTERVENTIONAL
Enrollment

319

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Major Depressive DisorderDepression
Interventions
DRUG

TC-5214

Tablet, oral, twice daily for 8 weeks

DRUG

Placebo

Tablet, oral, twice daily for 8 weeks

Trial Locations (51)

Unknown

Research Site, Tuscaloosa

Research Site, Tucson

Research Site, Little Rock

Research Site, Chino

Research Site, Costa Mesa

Research Site, Encino

Research Site, Escondido

Research Site, Los Alamitos

Research Site, Oceanside

Research Site, Pico Rivera

Research Site, San Diego

Research Site, Torrance

Research Site, Hamden

Research Site, Coral Springs

Research Site, Jacksonville

Research Site, Orange City

Research Site, Orlando

Research Site, Tampa

Research Site, Chicago

Research Site, Prairie Village

Research Site, Florence

Research Site, Shreveport

Research Site, St Louis

Research Site, New York

Research Site, Rochester

Research Site, Staten Island

Research Site, Cincinnati

Research Site, Dayton

Research Site, Middleburg Heights

Research Site, Portland

Research Site, Salem

Research Site, Norristown

Research Site, Charleston

Research Site, Dallas

Research Site, Houston

Research Site, Woodstock

Research Site, Seattle

Research Site, Visakhapatnam

Research Site, Guntur

Research Site, Ahmedabad

Research Site, Rajkot

Research Site, Mangalore

Research Site, Aurangabad

Research Site, Pune

Research Site, Nashik

Research Site, Jaipur

Research Site, Khātīpura

Research Site, Madurai

Research Site, Varanasi

Research Site, Kanpur

Research Site, Mysore

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Targacept Inc.

INDUSTRY

lead

AstraZeneca

INDUSTRY